ID

42476

Descripción

Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).

Link

https://leoss.net

Palabras clave

  1. 2/7/21 2/7/21 - Sarah Riepenhausen
  2. 15/7/21 15/7/21 - Sarah Riepenhausen
  3. 16/7/21 16/7/21 - Sarah Riepenhausen
Titular de derechos de autor

LEOSS

Subido en

16 de julio de 2021

DOI

10.21961/mdm:42476

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients

Apheresis therapy details

Type of apheresis therapy that was performed
Descripción

Type of apheresis therapy that was performed

Alias
UMLS CUI-1
C0005791
UMLS CUI-2
C0332307
Therapeutic plasma exchange
Descripción

Therapeutic plasma exchange

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032113
CytoSorb® therapy
Descripción

CytoSorb® therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3521106
UMLS CUI [1,2]
C0079189
Double Filtration Plasmapheresis (DFPP)
Descripción

Double Filtration Plasmapheresis (DFPP)

Tipo de datos

boolean

Alias
UMLS CUI [1]
C5200809
Other type of apheresis therapy
Descripción

Other type of apheresis

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0005791
UMLS CUI [1,3]
C0332307
Indicate other type of apheresis therapy
Descripción

Indicate other type of apharesis

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0205394
UMLS CUI [1,2]
C0005791
UMLS CUI [1,3]
C0332307
UMLS CUI [1,4]
C1521902
Treatment initiated in disease phase
Descripción

Treatment initiated in disease phase

Alias
UMLS CUI-1
C0005791
UMLS CUI-2
C0457338
UMLS CUI-3
C1704686
Phase when apheresis therapy has started
Descripción

Indicate in which disease phase the apheresis therapy was started.

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C0005791
UMLS CUI [1,2]
C0457338
UMLS CUI [1,3]
C1704686
Treatment details
Descripción

Treatment details

Alias
UMLS CUI-1
C0005791
UMLS CUI-2
C0087111
UMLS CUI-3
C1522508
Quantity of the average plasma volume per treatment
Descripción

Indicate quantity of the average plasma volume per treatment (apheresis therapy).

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C0032127
UMLS CUI [1,2]
C1510992
UMLS CUI [1,3]
C1265611
UMLS CUI [1,4]
C0005791
Overall number of treatments
Descripción

Please indicate the number of treatment sessions during the observational period

Tipo de datos

text

Alias
UMLS CUI [1,1]
C0005791
UMLS CUI [1,2]
C0750480
Duration of treatment
Descripción

Please indicate the number of days when apheresis has been applied

Tipo de datos

text

Unidades de medida
  • day
Alias
UMLS CUI [1,1]
C0005791
UMLS CUI [1,2]
C0449238
UMLS CUI [1,3]
C0439810
day
Perceived therapeutic effect
Descripción

Indicate if the treating physician experience a therapeutic effect.

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1710470
UMLS CUI [1,2]
C1527144
UMLS CUI [1,3]
C0005791
UMLS CUI [1,4]
C0022423
Is data entry for this section finished?
Descripción

Is data entry for this section finished?

Alias
UMLS CUI-1
C4684556
UMLS CUI-2
C1828479
UMLS CUI-3
C0205197
Is data entry for this section finished?
Descripción

Is data entry for this section finished?

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C4684556
UMLS CUI [1,2]
C1828479
UMLS CUI [1,3]
C0205197

Similar models

Apheresis therapy details

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Type of apheresis therapy that was performed
C0005791 (UMLS CUI-1)
C0332307 (UMLS CUI-2)
Therapeutic plasma exchange
Item
Therapeutic plasma exchange
boolean
C0032113 (UMLS CUI [1])
CytoSorb® therapy
Item
CytoSorb® therapy
boolean
C3521106 (UMLS CUI [1,1])
C0079189 (UMLS CUI [1,2])
Double Filtration Plasmapheresis (DFPP)
Item
Double Filtration Plasmapheresis (DFPP)
boolean
C5200809 (UMLS CUI [1])
Other type of apheresis
Item
Other type of apheresis therapy
boolean
C0205394 (UMLS CUI [1,1])
C0005791 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
Indicate other type of apharesis
Item
Indicate other type of apheresis therapy
text
C0205394 (UMLS CUI [1,1])
C0005791 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
Item Group
Treatment initiated in disease phase
C0005791 (UMLS CUI-1)
C0457338 (UMLS CUI-2)
C1704686 (UMLS CUI-3)
Item
Phase when apheresis therapy has started
integer
C0005791 (UMLS CUI [1,1])
C0457338 (UMLS CUI [1,2])
C1704686 (UMLS CUI [1,3])
Code List
Phase when apheresis therapy has started
CL Item
Uncomplicated phase (1)
CL Item
Complicated phase (2)
CL Item
Critical Phase (3)
CL Item
Recovery Phase (4)
CL Item
Unknown (5)
Item Group
Treatment details
C0005791 (UMLS CUI-1)
C0087111 (UMLS CUI-2)
C1522508 (UMLS CUI-3)
Item
Quantity of the average plasma volume per treatment
integer
C0032127 (UMLS CUI [1,1])
C1510992 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0005791 (UMLS CUI [1,4])
Code List
Quantity of the average plasma volume per treatment
CL Item
30 - 44 ml/kg (1)
CL Item
45 - 60 ml/kg (2)
CL Item
> 60 ml/kg (3)
CL Item
Not done (4)
CL Item
Unknown (5)
Treatments count
Item
Overall number of treatments
text
C0005791 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
Duration of treatment
Item
Duration of treatment
text
C0005791 (UMLS CUI [1,1])
C0449238 (UMLS CUI [1,2])
C0439810 (UMLS CUI [1,3])
Item
Perceived therapeutic effect
integer
C1710470 (UMLS CUI [1,1])
C1527144 (UMLS CUI [1,2])
C0005791 (UMLS CUI [1,3])
C0022423 (UMLS CUI [1,4])
Code List
Perceived therapeutic effect
CL Item
Yes (1)
CL Item
No (2)
CL Item
Unknown (3)
Item Group
Is data entry for this section finished?
C4684556 (UMLS CUI-1)
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
Is data entry for this section finished?
Item
Is data entry for this section finished?
boolean
C4684556 (UMLS CUI [1,1])
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial